Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Boehringer Ingelheim
Mallinckrodt
McKesson
Queensland Health
Chinese Patent Office
Medtronic
Cipla

Generated: May 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,886,036

« Back to Dashboard

Summary for Patent: 5,886,036
Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/822,071
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,886,036
Patent Claims: 1. A combination pharmaceutical agent for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and another HIV protease inhibiting compound.

2. The combination of claim 1 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

3. The combination of claim 1 wherein the other HIV protease inhibiting compound is Ro 31-8959.

4. The combination of claim 1 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the other HIV protease inhibiting compound are each formulated as separate compositions.

5. The combination of claim 4 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl) -amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at the same time.

6. The combination of claim 4 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at different times.

7. A combination pharmaceutical agent for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and Ro 31-8959.

8. A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and another HIV protease inhibiting compound.

9. The combination of claim 8 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

10. The combination of claim 8 wherein the other HIV protease inhibiting compound is Ro 31-8959.

11. The combination of claim 8 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the other HIV protease inhibiting compound are each formulated as separate compositions.

12. The combination of claim 11 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at the same time.

13. The combination of claim 11 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at different times.

14. A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and Ro 31-8959.

15. (2S,3 S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl )valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-h ydroxyhexane or a pharmaceutically acceptable salt thereof and another HIV protease inhibitor for concomitant administration for the treatment of an HIV infection.

16. (2S,3S,5S)- 5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valin yl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxy hexane or a pharmaceutically acceptable salt thereof and Ro 31-8959 for concomitant administration for the treatment of an HIV infection.

17. A combination pharmaceutical agent for administration to a human for the treatment of an HIV infection comprising:

a) a first pharmaceutical composition comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and

b) a second pharmaceutical composition comprising another HIV protease inhibiting compound.

18. The combination of claim 17 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

19. The combination of claim 17 wherein the other HIV protease inhibiting compound is Ro 31-8959.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chubb
Merck
Citi
Federal Trade Commission
Medtronic
US Department of Justice
Fish and Richardson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.